Drug Trial Radar · NCT04502693
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,657
Actual
Start
Aug 14, 2020
Primary completion
Sep 13, 2022
Study completion Sep 13, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 25 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety were evaluated in the study.
Conditions
- Infections, Meningococcal
Interventions
rMenB+OMV NZ vaccineCombination product
rMenB+OMV NZ vaccine was administered intramuscularly.
Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)Biological
MenACWY vaccine was administered intramuscularly.
PlaceboCombination product
Placebo was administered intramuscularly.
MenABCWY-1Combination product
Lot 1 of the MenABCWY vaccine was administered intramuscularly.
MenABCWY-2Combination product
Lot 2 of the MenABCWY vaccine was administered intramuscularly.
MenABCWY-3Combination product
Lot 3 of the MenABCWY vaccine was administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M), 2-dose(0,6-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWYTime frame: At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group, and Day 31 for ACWY group)
- Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose (0,2-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWYTime frame: At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule] and Day 31 for ACWY group)
- Percentage of Participants Whose Sera Kill Greater Than or Equal to (>=) 70% of the Strains Tested Using Enc-hSBA at 1 Month After the 3-dose (0,2,6-M) Schedule of rMenB+OMV and 2-dose(0,6-M) Schedule of rMenB+OMVTime frame: At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group)
- Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the 2-dose (0,2-M) Schedule of rMenB+OMVTime frame: At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule])
- Geometric Mean Titers (GMTs) Against Serogroups A, C, W and Y for Each Lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 Month After the Last Vaccination of MenABCWYTime frame: At 1 month after the last vaccination of MenABCWY (Day 211)
- Percentage of Participants With 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group), Relative to BaselineTime frame: At 1 month after vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY Group) compared to Day 1 (baseline)
- Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group)Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY group)
- Percentage of Blood Samples With Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose (Pooled Lots) and 2-dose(0,2-M) Schedule of rMenB+OMVTime frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule])
- Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the Last Vaccination in the ABCWY Group (Pooled Lots)Time frame: At 1 month after the last vaccination of MenABCWY (Day 211)
- Number of Participants With Any Solicited Local Adverse Events (AEs) After the First Study Intervention AdministrationTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of Participants With Any Solicited Local Adverse Events (AEs) After the Second Study Intervention AdministrationTime frame: During 7 days after the second study intervention administration occurring at Day 61
- Number of Participants With Any Solicited Local Adverse Events (AEs) After the Third Study Intervention AdministrationTime frame: During 7 days after the third study intervention administration occurring at Day 181
- Number of Participants With Any Solicited Systemic AEs After the First Study Intervention AdministrationTime frame: During 7 days after the first study intervention administration occurring at Day 1
- Number of Participants With Any Solicited Systemic AEs After the Second Study Intervention AdministrationTime frame: During 7 days after the second study intervention administration occurring at Day 61
- Number of Participants With Any Solicited Systemic AEs After the Third Study Intervention AdministrationTime frame: During 7 days after the third study intervention administration occurring at Day 181
- Number of Participants With Any Unsolicited AEs After the First Study Intervention AdministrationTime frame: During the 30 days after the first study intervention administration occurring at Day 1
- Number of Participants With Any Unsolicited AEs After the Second Study Intervention AdministrationTime frame: During the 30 days after the second study intervention administration occurring at Day 61
- Number of Participants With Any Unsolicited AEs After the Third Study Intervention AdministrationTime frame: During the 30 days after the third study intervention administration occurring at Day 181
- Number of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEsTime frame: Throughout the study period (Day 1 to Day 361)
Locations
112 sites in 7 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Bell Gardens, California
GSK Investigational Site
Canoga Park, California
GSK Investigational Site
Garden Grove, California
GSK Investigational Site
Inglewood, California
GSK Investigational Site
Los Gatos, California
GSK Investigational Site
Cutler Bay, Florida
GSK Investigational Site
Lake City, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Oviedo, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Adairsville, Georgia
GSK Investigational Site
Buford, Georgia
GSK Investigational Site
Columbus, Georgia
GSK Investigational Site
Hinesville, Georgia
GSK Investigational Site
Nampa, Idaho
GSK Investigational Site
Oak Brook, Illinois
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Bardstown, Kentucky
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Metairie, Louisiana
GSK Investigational Site
Beverly, Massachusetts
GSK Investigational Site
Fall River, Massachusetts
GSK Investigational Site
Grosse Pointe Woods, Michigan
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Petal, Mississippi
GSK Investigational Site
Missoula, Montana
GSK Investigational Site
Missoula, Montana
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Dayton, Ohio
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.